Fetal Support Tissue HC-HA/PTX3 for Vasculogenesis in Pericyte-Limited Tissue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods fail to effectively promote vasculogenesis and neurovasculogenesis, particularly in tissues lacking pericytes, leading to conditions such as ischemia, neuropathy, and abnormal angiogenesis.
Innovation Solution
Utilizing a fetal support tissue product containing a native or reconstituted heavy chain-hyaluronan/pentraxin 3 (HC-HA/PTX3) complex to reprogram pericytes and endothelial cells to progenitor phenotypes, promoting vasculogenesis and neurovasculogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to promote vasculogenesis, then existing therapeutic approaches are applied, but they fail to effectively promote vasculogenesis and neurovasculogenesis in tissues lacking pericytes
Solution Approach 1:
The patent changes the cellular state parameter by reprogramming pericytes to a progenitor phenotype using HC-HA/PTX3 complex, transforming them from a state that limits vasculogenesis to a state that promotes it. This parameter change enables the therapy to work in tissues that previously lacked the necessary cellular conditions for effective vasculogenesis promotion
Solution Approach 2:
The HC-HA/PTX3 complex acts as an intermediary agent that mediates the transformation of pericytes into progenitor cells. This intermediary facilitates the communication and cellular reprogramming needed to overcome the limitation of tissues lacking pericytes, enabling vasculogenesis promotion where conventional methods fail
2Reliability
If fetal support tissue product is used to reprogram cells, then vasculogenesis and neurovasculogenesis are promoted, but the complexity of the treatment increases
Solution Approach 1:
The patent extracts the key active component (HC-HA/PTX3 complex) from the complex fetal support tissue environment, isolating the essential elements needed for cell reprogramming and vasculogenesis promotion. This extraction simplifies the treatment by focusing on the critical components while removing unnecessary complexity
Solution Approach 2:
The treatment is segmented into specific actionable components: the HC-HA/PTX3 complex delivery system and the targeted cell reprogramming process. This segmentation allows for standardized, reproducible application of the therapy while maintaining the effectiveness of promoting vasculogenesis and neurovasculogenesis
Data Source
Figure 1
Figure 2A
Figure 2B~3A
AI summary
Disclosed herein are methods of promoting vasculogenesis, promoting neurovasculogenesis, or treating an ischemic condition, comprising contacting a tissue with a fetal support tissue product.